Sutro Biopharma Inc

Sutro Biopharma Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sutro Biopharma, Inc. engages in the drug discovery, development and manufacture of pharmaceutical products. It focuses on the next generation cancer and autoimmune therapeutics. The company was founded by James R. Swartz and Sutanto Widjaja on April 21, 2003 and is headquartered in South San Francisco, CA.

SOUTH SAN FRANCISCO, Calif., May 14, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will present at two upcoming virtual investor conferences on May 20 and June 2, 2021.

Sutro Biopharma to Participate in Upcoming Virtual Investor Conferences

SOUTH SAN FRANCISCO, Calif., May 7, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today reported its financial results for the quarter ended March 31, 2021, its recent business highlights, and provided a preview of anticipated selected milestones in 2021.

Sutro Biopharma Reports First Quarter 2021 Financial Results, Business Highlights and 2021 Anticipated Milestones

SOUTH SAN FRANCISCO, Calif., April 20, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the promotion of Chief Scientific Officer Trevor Hallam, Ph.D.

Sutro Biopharma Promotes Trevor Hallam, Ph.D., to President of Research and Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif., April 15, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Merck, known as MSD outside the United States and Canada, will make to Sutro a $15 million milestone payment for the initiation of an IND enabling toxicology study for the first program in its collaboration to develop novel cytokine derivative therapeutics for cancer and autoimmune disorders.

Sutro Biopharma Earns Milestone Payment from Cytokine Derivatives Collaboration with Merck

SAN FRANCISCO, April 8, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced that Chief Executive Officer, Bill Newell, will present at two upcoming virtual investor conferences on April 15 and May 5, 2021. Presentation Details 20th Annual Needham Virtual Healthcare Conference Date: Thursday, April 15, 2021 Presentation time: 2:15 p.m.

Sutro Biopharma to Present at Two Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., March 22, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today announced the strengthening of key leadership roles including the promotion of David Pauling, J.D.

Sutro Biopharma Strengthens Leadership Through Management Promotions and Expansion of Clinical Advisory Board

Sutro Biopharma, Inc. (STRO) delivered earnings and revenue surprises of -164.29% and -32.13%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Sutro Biopharma, Inc. (STRO) Reports Q4 Loss, Lags Revenue Estimates

SOUTH SAN FRANCISCO, Calif., March 18, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and autoimmune therapeutics, today reported its financial results for the year ended December 31, 2020, its recent business highlights, and provided a preview of anticipated selected milestones in 2021.

Sutro Biopharma Reports Full Year 2020 Financial Results and Provides Business Highlights and 2021 Anticipated Milestones

Sutro Biopharma, Inc. (STRO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Sutro Biopharma, Inc. (STRO) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

SOUTH SAN FRANCISCO, Calif., Jan. 21, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma Announces First Patient Dosed in the Dose-Expansion Study of STRO-002 in Patients with Ovarian Cancer

Sutro is a leader in CFPS and has major collaborations to prove it. Its early data is a lethal late line cancer is very promising.

Sutro: Leading Cell Free Protein Synthesis Company With Promising Early Data

SOUTH SAN FRANCISCO, Calif., Jan. 5, 2021 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma to Present at the 39th Annual J.P. Morgan Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 8, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma Announces Pricing of $126.0 Million Public Offering

Cantel Medical

iBio

iBio (NYSE: IBIO) shares are trading lower on Tuesday after the company announced a common stock offering. iBio's main area of business is plant-based protein expression technologies for vaccines and therapeutic proteins and developing and commercializing select biopharmaceutical product candidates.

Why iBio, Sutro And Cantel Medical Are Moving Today

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (Nasdaq: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma Announces Proposed Public Offering of 5 Million Shares of Common Stock

SOUTH SAN FRANCISCO, Calif., Dec. 7, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma Presents Data from Ongoing Phase 1 Dose-Escalation Study for STRO-001 for the Treatment of B-cell Non-Hodgkin Lymphoma at the 62nd American Society of Hematology Annual Meeting

One of the company's pipeline treatments shows encouraging results in ovarian cancer patients.

Why Sutro Biopharma Blasted 33% Higher on Friday

BioCryst Pharmaceuticals

Moderna

Eli Lilly

Sutro Biopharma (NASDAQ: STRO) shares are trading higher on Friday after the company announced interim data on its STRO-002 Phase 1 dose-escalation study for patients with ovarian cancer. Sutro Biopharma is a clinical stage company developing and manufacturing therapeutics.

Why BioCryst, Moderna And More Are Moving Today

Sutro Biopharma (STRO) is on the rise Friday with heavy trading of STRO stock despite the company not announcing anything new today. The post Sutro Biopharma: 7 Things for STRO Stock Investors to Know About the Biotech Company appeared first on InvestorPlace.

Sutro Biopharma: 7 Things for STRO Stock Investors to Know About the Biotech Company

Sutro Biopharma Inc. (NASDAQ: STRO) made a huge gain to close out the week after the firm provided an update from its ongoing dose-escalation in its ovarian cancer trial.

Sutro Bio's Ovarian Cancer Treatment Ready for the Next Level

SOUTH SAN FRANCISCO, Calif., Dec. 3, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 24, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

Sutro Biopharma to Host a Virtual KOL Event to Provide Clinical Update on Antibody-Drug Conjugate STRO-002 in Ovarian Cancer

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation oncology...

Sutro Biopharma Announces the Appointment of Diana Landa as Vice President of Regulatory Affairs and Annie Chang as Head of Investor Relations

SOUTH SAN FRANCISCO, Calif., Nov. 11, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development, and manufacturing company, today announced that Chief Executive Officer, Bill Newell, will participate in four upcoming virtual conferences in...

Sutro Biopharma to Participate in Four Upcoming Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 5, 2020 /PRNewswire/ -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage drug discovery, development and manufacturing company focused on the application of precise protein engineering and rational design to create next-generation cancer and...

News for Sutro Biopharma Inc Stock (STRO)